Moderna, Inc.

NASDAQ Global Select
Back to all articles
Bullish +65

Moderna stock rises on cancer vaccine data and fresh upgrades

AI-generated analysis

📈 Moderna stock surged over 100% in the past month following the release of positive Phase 3 cancer vaccine data from the INTerpath-001 trial.

🔬 The company achieved a historic first with its personalized mRNA cancer vaccine showing significantly improved recurrence-free survival in a study of more than 1,100 patients.

📊 Argus Research upgraded Moderna to Buy with an $180 price target, citing the transformative potential of the oncology pipeline.

💰 Despite the stock trading at $158.07, the company reported Q3 revenue of $145.0 million and an EPS loss of -$1.97 for the quarter ended July 31.

📉 Analyst consensus remains cautious with a Hold rating and average price target near $91, contrasting sharply with the recent stock rally.

🏥 The successful trial confirms that Moderna's oncology business is moving beyond a side story into a primary revenue-generating segment.

Bullish Signals
  • Moderna achieved a historic first as its personalized mRNA cancer vaccine delivered positive Phase 3 results, significantly improving recurrence-free survival in over 1,100 patients.
  • The company's stock price has gained more than 100% over the past month, reflecting strong investor confidence in the oncology pipeline following the INTerpath-001 readout.
  • Argus Research upgraded Moderna to a Buy rating and set an $180 price target, validating the strategic shift toward cancer therapies as a core business pillar.
Risk Factors
  • Analyst consensus remains Hold with an average price target of $91, which is substantially lower than the current trading price of $158.07, indicating lingering skepticism about near-term financial performance.
Full Analysis
Moderna Inc. shares rose to $158.07 on September 17, 2026, driven by positive Phase 3 clinical data for its personalized mRNA cancer vaccine and a wave of fresh analyst upgrades. The company's stock gained over 100% in the past month as investors re-evaluate oncology as a core growth driver rather than a side story following the successful INTerpath-001 trial readout. The pivotal clinical update revealed that Moderna and Merck's combination therapy significantly improved recurrence-free survival in a Phase 3 study involving more than 1,100 patients. This represents the first positive Phase 3 result for a personalized mRNA cancer vaccine, marking a major milestone that validates the company's strategic pivot toward oncology applications. Wall Street sentiment remains mixed despite the bullish clinical news, with Argus Research raising its rating to Buy and setting an $180 price target. However, other analysts like Rothschild & Co maintained a Sell rating, while consensus targets hover around $91, creating a valuation tension between the company's high stock price and its current loss-making quarterly financial profile.